Lumora strengthens team and appoints Hayden Jeffreys as Commercial Director
Cambridge, UK, Monday 28 January 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, has announced the appointment of Hayden Jeffreys as Commercial Director.
Hayden joins Lumora as part of the company’s strategy to further commercialise its molecular testing technologies. This includes BART (Bioluminescent Assay in Real Time), which has been licensed to 3M for in vitro molecular testing in food, beverages, in its latest innovation, the 3M™ Molecular Detection System.
Hayden joins Lumora from Lab21, a personalised medicine diagnostic specialist. Hayden was Divisional Director-Diagnostic Products and part of the management team that quadrupled revenues in four years and helped created a major consolidation and technology platform for future growth. Prior to Lab21, Hayden held positions at Invitron, Gen-Probe and Molecular Light Technology
Laurence Tisi, CEO of Lumora said: “Lumora has developed some great technologies, and we have secured some significant licensing deals. Hayden brings a wealth of experience in commercialising molecular diagnostic systems particularly in the medical sector and this will be crucial to expanding our portfolio of products and licenses. The medical molecular diagnostic market is the fastest growing sector of the diagnostic industry and Hayden brings the direct experience we need to gain the most from this rapidly expanding area.
Hayden Jeffreys added: “This is a really exciting time to be joining Lumora. The licensing deal with 3M shows how the company’s technologies can be applied to fixing problems in the real world. At the same time, Lumora has a number of other technology platforms with wide ranging applications in the clinical field and I am confident that the benefits demonstrated in the industrial area will answer some real challenges in diagnostic development in a wide range of disease areas making Lumora the ideal partner as companies look to move molecular testing closer to the patient.”
For further information please contact:
Tony Stephenson, PR Consultant
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Notes to Editors:
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.
Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Cambridge Enterprise, (University of Cambridge) Tate Lyle Ventures LP, and Catapult Venture Managers Ltd.
